But it failed to demonstrate significant weight loss in six clinical trials, and its development was terminated because of those failures
BPC-157 has been investigated in Phase II clinical trials for inflammatory bowel disease therapy, where it demonstrated a favorable safety profile with no reported toxicity or adverse effects
A High horsepower, low RPM, Horizontal Seal-less pump and bearing unit is Suspended over the pit on I-beams
BPC-157 has not been proven safe or effective for any condition and is not eligible for inclusion on the 503B Bulks List for compounding. FDA Review Memorandum, 2023 In other words, BPC157 does not meet FDA standards for legal use in clinical practice
It is supplied as a white to off-white lyophilized powder, soluble in water and bacteriostatic water, and verified at 99% purity by reversed-phase HPLC
That is where BPC-157 comes in